Aesica Unveils a New High Capacity Manufacturing Facility
News Sep 19, 2013
Aesica has announced the creation of a new High Capacity Manufacturing Facility following a £30 million investment at its Queenborough, Kent site.
The 10,000 sq. m expansion has been constructed for the production of a solid dose medication used in treating one of the world’s most common lifestyle diseases: Type 2 diabetes in adults.
Following today’s official opening, commercial production at the facility will commence in November. The facility contains a large amount of highly technical and specialist equipment including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system.
Her Majesty’s Lord- Lieutenant of Kent, Viscount De L’Isle attended the ceremony to unveil the opening of the new facility, doing so in recognition of the contribution that Aesica is making to the regional economy, both in terms of the creation of new jobs and commercial expansion.
Aesica Pharmaceuticals is well established as a manufacturer and a major exporter of formulated products with this latest investment reflecting the continued growth in export demand experienced by the company. This specific product manufactured at the new facility has global sales and is set for worldwide export.
Aesica is already a strong, committed, local employer in the Queenborough area and with this latest investment and expansion, the facility will have a dedicated workforce of 55 technicians who will be recruited locally and trained on site.
The design of the facility will allow the current capacity to be more than doubled in the future which would require a further additional 50 staff to be recruited.
Dr Robert Hardy, CEO of Aesica Pharmaceuticals commented: “The new investment and opening of the High Capacity Manufacturing Facility marks another key milestone for our company and a further step towards achieving our vision to be the world’s number one supplier of APIs and formulated products to the pharmaceutical industry.”
He continued: “The formulation of the solid dose product for the treatment of Type 2 diabetes is a perfect example of the type of high quality and high healthcare demand drugs that we manufacture for supply to the international market place.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE